CR20210364A - Compuestos de quinolina como inhibidores de quinasas tam y met - Google Patents

Compuestos de quinolina como inhibidores de quinasas tam y met

Info

Publication number
CR20210364A
CR20210364A CR20210364A CR20210364A CR20210364A CR 20210364 A CR20210364 A CR 20210364A CR 20210364 A CR20210364 A CR 20210364A CR 20210364 A CR20210364 A CR 20210364A CR 20210364 A CR20210364 A CR 20210364A
Authority
CR
Costa Rica
Prior art keywords
sup
tam
inhibitors
quinoline compounds
met kinases
Prior art date
Application number
CR20210364A
Other languages
English (en)
Inventor
Oren T Mcnulty
Adam Cook
Ronald Jay Hinklin
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR20210364A publication Critical patent/CR20210364A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente, se proporcionan compuestos de la Fórmula <strong>I</strong>: <img height="284" src="data:image/png;base64,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 (***)
CR20210364A 2019-01-03 2020-01-02 Compuestos de quinolina como inhibidores de quinasas tam y met CR20210364A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962787965P 2019-01-03 2019-01-03
US201962858819P 2019-06-07 2019-06-07
US201962947720P 2019-12-13 2019-12-13
PCT/IB2020/050009 WO2020141470A1 (en) 2019-01-03 2020-01-02 Quinoline compounds as inhibitors of tam and met kinases

Publications (1)

Publication Number Publication Date
CR20210364A true CR20210364A (es) 2021-08-18

Family

ID=69185648

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210364A CR20210364A (es) 2019-01-03 2020-01-02 Compuestos de quinolina como inhibidores de quinasas tam y met

Country Status (17)

Country Link
US (1) US20200216416A1 (es)
EP (1) EP3906234A1 (es)
JP (1) JP2022515880A (es)
KR (1) KR20210110664A (es)
CN (1) CN113302188A (es)
AU (1) AU2020205035A1 (es)
BR (1) BR112021012956A2 (es)
CA (1) CA3125559A1 (es)
CO (1) CO2021008535A2 (es)
CR (1) CR20210364A (es)
IL (1) IL284570A (es)
MA (1) MA54656A (es)
MX (1) MX2021008136A (es)
SG (1) SG11202106897XA (es)
TW (1) TWI745824B (es)
UY (1) UY38536A (es)
WO (1) WO2020141470A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210049862A (ko) * 2018-08-24 2021-05-06 난징 트렌스테라 바이오사이언스즈 컴퍼니 리미티드 일종의 신형 퀴놀린 유도체 억제제
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
CN116783166A (zh) * 2021-02-01 2023-09-19 江苏恒瑞医药股份有限公司 二甲酰胺类化合物、其制备方法及其在医药上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732613B2 (en) * 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
NZ586630A (en) * 2008-01-23 2011-12-22 Bristol Myers Squibb Co 4-Pyridinone compounds and their use for cancer
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
ES2749726T3 (es) * 2014-12-25 2020-03-23 Ono Pharmaceutical Co Derivado de quinolina
KR101829998B1 (ko) 2015-11-04 2018-02-19 롬엔드하스전자재료코리아유한회사 착색 감광성 수지 조성물 및 이를 이용한 차광성 스페이서
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN110041316B (zh) * 2018-01-17 2022-04-19 药捷安康(南京)科技股份有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物

Also Published As

Publication number Publication date
KR20210110664A (ko) 2021-09-08
SG11202106897XA (en) 2021-07-29
EP3906234A1 (en) 2021-11-10
AU2020205035A1 (en) 2021-07-22
UY38536A (es) 2020-08-31
MX2021008136A (es) 2021-08-11
US20200216416A1 (en) 2020-07-09
JP2022515880A (ja) 2022-02-22
CN113302188A (zh) 2021-08-24
CO2021008535A2 (es) 2021-07-19
TW202039465A (zh) 2020-11-01
IL284570A (en) 2021-08-31
TWI745824B (zh) 2021-11-11
CA3125559A1 (en) 2020-07-09
BR112021012956A2 (pt) 2021-10-26
WO2020141470A1 (en) 2020-07-09
MA54656A (fr) 2022-04-06

Similar Documents

Publication Publication Date Title
CR20210098A (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
SA519401541B1 (ar) [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX2020013014A (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
WO2016106331A8 (en) Mutant idh1 inhibitors useful for treating cancer
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
CR20210364A (es) Compuestos de quinolina como inhibidores de quinasas tam y met
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
IL219644A0 (en) Kinase inhibitors and methods of use thereof
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2022013482A (es) Compuestos utiles para inhibir la quinasa ret.
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
EA202190393A1 (ru) СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TAM- И Met-КИНАЗ
ZA202212095B (en) Il4i1 inhibitors and methods of use
EA201990939A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ